Investor Relations


Date Title and Summary Additional Formats
Toggle Summary Understanding the Difference between COVID-19 Symptoms and Sinus Disease World Sinus Health Awareness Day 2021
September 14, 2021–Alexandria, Virginia —The American Academy of Otolaryngology–Head and Neck Surgery (AAO-HNS), in partnership with Intersect ENT, Inc., launched a public education campaign that provides clinically-developed information by experts in the field aimed at helping people better
Toggle Summary U.S. Nationwide Commercial Availability of the VenSure™ Balloon Sinus Dilation System and Cube™ Navigation System Highlight Intersect ENT’s Continued Commitment to Providing Innovative, Solutions for Patients with Chronic Rhinosinusitis
VenSure and Cube Join the Company’s Portfolio of Localized Drug Delivery Creating an Integrated Offering of ENT Technologies to Treat CRS MENLO PARK, Calif. --(BUSINESS WIRE)--Jul. 26, 2021-- Intersect ENT ® , Inc. (Nasdaq: XENT), a global ear, nose and throat (“ENT”) medical technology leader
Toggle Summary Today's Research Report Coverage on Medical Equipment Stocks -- Lantheus, Intersect ENT, CHF Solutions, and ReWalk Robotics
NEW YORK , August 25, 2017 /PRNewswire/ -- If you want a Stock Review on LNTH, XENT, CHFS, or RWLK then come over to and sign up for your free customized report today. Today's attention is focused onto the Medical Appliances and Equipment industry, which is
Toggle Summary Teresa L. Kline Joins Intersect ENT’s Board of Directors
Toggle Summary Study Indicates Cost Effectiveness of Intersect ENT’s PROPEL Implant for Chronic Sinusitis Study Author Assesses Significant Productivity Loss from Chronic Sinusitis
Toggle Summary Sinexus Welcomes New CEO and Completes Series B
Toggle Summary Sinexus changes name to Intersect ENT, Initiates Pivotal Study
Toggle Summary Real-World Evidence Study Demonstrates Intersect ENT’s PROPEL® Sinus Implant Reduces Healthcare Resource Utilization
Data from first-of-its-kind study published in Current Medical Research and Opinion Patients receiving PROPEL ® following endoscopic sinus surgery had statistically significant lower healthcare resource utilization over a postoperative period of 18 months, including all-cause otolaryngologist,
Toggle Summary ntersect ENT Announces Publication of PROGRESS Studyof Steroid Releasing Implant in Patients With Frontal Sinus Disease
Toggle Summary ntersect ENT Announces Positive Preliminary Clinical Results for the PROPEL Mini Steroid Releasing Implant in Patients with Frontal Sinus Disease